Compare WhiteOak Capital Pharma and Healthcare Fund vs ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund
Risk | Very High | Very High |
Rating | - | 5.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 2.38 | 1.86 |
NAV | ₹13.06 | ₹37.51 |
Fund Started | 16 Jan 2024 | 25 Jun 2018 |
Fund Size | ₹508.73 Cr | ₹6455.55 Cr |
Exit Load | Exit load of 1%, if redeemed within 1 months. | Exit load of 1% if redeemed within 15 days. |
Risk
Very High
Very High
Rating
-
5.0
Min SIP Amount
₹100
₹100
Expense Ratio
2.38
1.86
NAV
₹13.06
₹37.51
Fund Started
16 Jan 2024
25 Jun 2018
Fund Size
₹508.73 Cr
₹6455.55 Cr
Exit Load
Exit load of 1%, if redeemed within 1 months.
Exit load of 1% if redeemed within 15 days.
1 Year | -0.04% | -1.13% |
3 Year | - | 25.33% |
5 Year | - | 16.15% |
1 Year
-0.04%
-1.13%
3 Year
-
25.33%
5 Year
-
16.15%
Equity | 98.58% | 97.87% |
Cash | -4.95% | 2.13% |
Equity
98.58%
97.87%
Cash
-4.95%
2.13%
Top 10 Holdings |
|
|
Top 10 Holdings
Sun Pharmaceutical Industries Ltd. | 10.91% |
JB Chemicals & Pharmaceuticals Ltd. | 8.38% |
Max Healthcare Institute Ltd. | 6.90% |
Laurus Labs Ltd. | 5.44% |
Fortis Healthcare Ltd. | 5.25% |
Lupin Ltd. | 4.79% |
Divi's Laboratories Ltd. | 4.50% |
Cipla Ltd. | 3.90% |
Alkem Laboratories Ltd. | 2.76% |
Neuland Laboratories Ltd. | 2.49% |
Sun Pharmaceutical Industries Ltd. | 12.05% |
Cipla Ltd. | 7.90% |
Dr. Reddy's Laboratories Ltd. | 7.82% |
Divi's Laboratories Ltd. | 7.10% |
Mankind Pharma Ltd. | 6.44% |
Lupin Ltd. | 5.78% |
Aurobindo Pharma Ltd. | 5.19% |
Alkem Laboratories Ltd. | 3.66% |
Cohance Lifesciences Ltd. | 3.01% |
Syngene International Ltd. | 2.98% |
Name | - | - |
Start Date | - | - |
Name
-
-
Start Date
-
-
Description | The Scheme seeks to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 16 Jan 2024 | 25 Jun 2018 |
Description
The Scheme seeks to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies.
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
Launch Date
16 Jan 2024
25 Jun 2018